Trump Administration Announces Deals to Lower Prices and Expand Access to Popular Weight-Loss and Diabetes Drugs
President Trump announced deals to lower prices and expand access to GLP-1 weight-loss and diabetes drugs for Medicare, Medicaid, and uninsured patients.
Overview
President Trump announced deals with Eli Lilly and Novo Nordisk to reduce prices and expand access to popular GLP-1 weight-loss and diabetes medications like Zepbound and Wegovy.
The TrumpRx program launches in January for uninsured individuals, offering GLP-1 drugs at reduced prices, starting from $149-$350 monthly, with Medicare access following next summer.
Medicare will expand coverage for GLP-1 drugs to include obesity and related conditions, benefiting an additional 10% of beneficiaries, with eligible patients paying as low as $50 monthly.
Drugmakers will lower Medicare prices for GLP-1 drugs to $245 monthly, with a $50 copay for beneficiaries, and offer reduced prices to state Medicaid programs after negotiations.
These initiatives aim to address high costs and limited access to obesity treatments for over 100 million Americans, with new pricing agreements rolling out from January to mid-2026.
Analysis
Center-leaning sources cover the White House's new drug deals neutrally, focusing on factual reporting of the announcement. They detail the agreements for lower obesity and diabetes drug prices, including copay specifics and eligibility. The coverage incorporates diverse perspectives, such as administration officials, medical professionals, and an economist, to provide a balanced overview of the initiative's scope and potential implications.